Salient’s Aquamantys System uses Transcollation technology, a combination of radiofrequency energy and saline that enables surgeons to prevent and stop bleeding of soft tissue and bone during surgery and thereby decrease the risk of blood transfusions.

The technology has already been used to improve patient care for patients in orthopaedic reconstruction, spine, brain tumor resection, trauma, and surgical oncology procedures.

The clinical benefits of Salient’s Transcollation technology during partial nephrectomy procedures have been documented in nine published peer-reviewed articles.

Salient president and CEO Joseph Army said this is particularly beneficial to older patients and those suffering from conditions as hypertension and diabetes.

"Introducing the Aquamantys System to these procedures doubles the number of solid organ surgeries in which patients can be treated with Transcollation technology," Army said.